carboplatin + cyclophosphamide + etoposide

This is a combination chemotherapy regimen consisting of three cytotoxic agents—carboplatin, cyclophosphamide, and etoposide. Each drug has a distinct mechanism of action targeting cancer cells: - **Carboplatin** is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication by forming covalent bonds with DNA bases. - **Etoposide** inhibits topoisomerase II, leading to double-stranded breaks in DNA during the cell cycle. This combination has been used primarily as high-dose chemotherapy for refractory or relapsed cancers such as multiple myeloma and germ cell tumors (GCT), often in conjunction with autologous bone marrow transplantation. The regimen aims to overcome resistance to standard therapies by using synergistic mechanisms of action from each component[1][2][6].

Other names

carboplatin, cyclophosphamide, and etoposide combination